Omron Corporation CEO Junta Tsujinaga says consumer wearables like the Apple Watch are for wellness, not medical diagnosis. The company remains focused on its clinically validated healthcare devices while expanding its manufacturing base in India with a new Chennai plant.
Omron Corporation’s president and CEO, Junta Tsujinaga, has addressed concerns about the growing health-tracking capabilities of smartwatches. Speaking during a recent event, Tsujinaga clarified that consumer wearables like the Apple Watch do not pose a direct threat to Omron’s dedicated medical blood pressure monitoring business. The company maintains that its devices are designed for clinical diagnosis, a standard that separates them from general wellness gadgets.
Clinical Validation as a Competitive Edge
The core distinction, according to the company, lies in regulatory approval and accuracy. While Apple recently received FDA clearance for hypertension notifications, these are categorized as a notification system rather than a diagnostic medical device. In contrast, Omron’s monitors are built to meet strict standards set by medical institutions like the European Society of Hypertension and the Association for the Advancement of Medical Instrumentation. Doctors rely on these clinical readings for treatment decisions, which remains the primary driver of demand for Omron's professional-grade equipment. Interestingly, Apple even utilized Omron's Evolv wireless monitor as a benchmark to validate its own health-tracking features, which the company views as an acknowledgement of its industry-standard status.
Expanding Manufacturing Footprint in India
Beyond defending its market position, Omron is scaling its operations to meet rising global and domestic demand. In late October 2026, the company commenced production at its new manufacturing facility near Chennai, India. This strategic move is designed to support both local requirements and export goals, with plans to reach an annual production capacity of 3 million blood pressure monitors by 2028. This expansion reflects the company's commitment to India as a critical hub for its healthcare division, ensuring that its medical-grade devices remain accessible to growing markets.
Strategic Shift to Industrial Automation
While healthcare continues to be a major revenue pillar, contributing nearly $1 billion in annual sales, Omron is simultaneously transforming its broader business portfolio. The company is reallocating capital toward its Industrial Automation Business, as seen in the $675 million acquisition of U.S.-based OnLogic. This move aims to integrate artificial intelligence and industrial computing into factory environments, diversifying the company’s focus beyond just medical devices. As Omron streamlines its operations—including the recent divestment of its device and module solutions unit—the leadership is balancing its legacy medical footprint with aggressive expansion in smart manufacturing.
Business Risks and Market Outlook
For investors and stakeholders, the long-term monitorable is how the company balances these two distinct divisions. While the medical business has a clear advantage in clinical settings, the rise of lower-cost consumer wearables presents a competitive risk in the non-clinical, general health-monitoring market. Additionally, like many global manufacturers, Omron faces potential pressure from rising raw material costs, logistics expenses, and shifts in international trade policies, which can impact profit margins. Moving forward, the success of the new Chennai facility and the integration of the industrial automation acquisitions will be key factors for the company’s financial performance.